Eflapegrastim - Hanmi Pharmaceutical/Spectrum Pharmaceuticals

Drug Profile

Eflapegrastim - Hanmi Pharmaceutical/Spectrum Pharmaceuticals

Alternative Names: Granulocyte colony-stimulating factor long-acting - Hanmi Pharmaceutical/Spectrum; Granulocyte colony-stimulating factor long-acting - Spectrum Pharmaceuticals; HM-10460A; HNK-460; LAPS-GCSF; Long-acting G-CSF analogue; ROLONTIS; SPI-2012

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Hanmi Pharmaceutical
  • Developer Hanmi Pharmaceutical; Spectrum Pharmaceuticals
  • Class Chemoprotectants; Granulocyte colony-stimulating factors; Immunoglobulin Fc fragments; Polyethylene glycols; Small molecules
  • Mechanism of Action Granulocyte stimulants; Haematopoiesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Neutropenia

Most Recent Events

  • 02 Nov 2017 Spectrum Pharmaceuticals announces intention to submit BLA to US FDA for Neutropenia in fourth quarter of 2018
  • 01 Aug 2017 Spectrum Pharmaceuticals completes enrolment in the ADVANCE trial for Neutropaenia (Chemotherapy-induced) in USA (SC) (NCT02643420)
  • 11 May 2017 Spectrum Pharmaceuticals initiates enrolment in a phase I trial for Neutropenia (Chemotherapy-induced) in USA (NCT03135951)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top